Recently, the Class I innovative product Gumarontinib tablets of Haihe Biopharma Co., Ltd. is approved with conditions by China NMPA. This drug is indicated for treating the locally advanced or metastatic non-small cell lung cancer(NSCLC) with METex14 skipping mutation.

Gumarontinib can selectively inhibit the activity of c-Met kinase, thereby inhibiting the proliferation, migration and invasion of tumor cells. The marketing of this drug provides a new treatment option available for patients with locally advanced or metastatic NSCLC with METex14 skipping mutation.